March 19, 2019 — The Foundation for the National Institutes of Health (FNIH) has launched a new project that will develop better vaccines to prevent tuberculosis (TB). Through the new project, titled “Understanding the mechanisms of intravenous BCG-induced protection against TB in NHP,” researchers will analyze the effects of delivering the only current TB vaccine, Bacillus Calmette Guerin (BCG), through a new route, intravenously (IV), in an attempt to better prevent TB.
January 25, 2019 —Since 2011, the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium has been shedding new light on diabetes – a disease that affects more than 30 million people in the United States – by examining the function of the beta cell. Found within the pancreas, the beta cell has the critical role of producing and secreting insulin – an essential hormone necessary for the control of blood sugar and metabolism. In patients with diabetes, the beta cell is attacked or destroyed by the immune system (Type 1 diabetes) or is unable to produce enough insulin to control blood sugar levels (Type 2 diabetes).
December 14, 2018 —The Foundation for the National Institutes of Health (FNIH) announces that the Accelerating Medicines Partnership (AMP) is extending the Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE) & Related Autoimmune Disorders program to a sixth year.
December 13, 2018 —Today, the National Institutes of Health (NIH) Advisory Committee to the Director (ACD) issued a follow-up report on the Moderate Alcohol and Cardiovascular Health Trial (MACH). The following is the FNIH’s statement on the report.
November 8, 2018 — The Foundation for the National Institutes of Health (FNIH) and Jayne Koskinas Ted Giovanis (JKTG) Foundation for Health and Policy are proud to announce renewed support for the intramural research training of two young fellows at the National Institutes of Health (NIH). The fellowships are being made possible by a generous donation from the JKTG Foundation for Health and Policy to the FNIH.
November 7, 2018— A program at the National Institutes of Health to provide hands-on laboratory experience to undergraduate students from across the United States will continue for another four years, thanks to a grant from the Amgen Foundation to the Foundation for the National Institutes of Health (FNIH). The Amgen Scholars Program at NIH aims to break down barriers for many students who otherwise would not have the opportunity to engage in science at the world’s top educational and research institutions. Financial support for students is a critical component of the program, which seeks to ensure that eligible students, regardless of their financial status, can participate. The program is made possible by a grant from the Amgen Foundation to the FNIH.
October 2, 2018 — Bacterial infections acquired in hospitals are a major concern for healthcare providers and their patients. In particular, hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) are severe infections that cause patient deaths. As bacterial resistance to antibiotics increases, new treatments to combat these infections are desperately needed. Yet, measuring the effectiveness of new treatments continues to be a challenge due to a lack of well-defined clinical trial endpoints (outcomes measured to determine whether a therapy being studied is beneficial to patients).
September 21, 2018 - Today, Vice President Joe Biden and Dr. Jill Biden are hosting the national Biden Cancer Summit in Washington, D.C. This event is one of more than 350 Biden Cancer Community Summits convening across the country to bring together patients and caregivers with the scientific community to help promote new solutions for tackling cancer and share stories of the tremendous resilience and strength shown by those who have been touched by the disease and remain #CancerFIERCE.
August 2, 2018 — The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium (BC) has launched a project, under its Inflammation and Immunity Steering Committee, to seek regulatory qualification of new biological markers (biomarkers) that predict the change in joint damage over time from osteoarthritis (OA) in the knee. The PROGRESS OA: Clinical Evaluation and Qualification of Osteoarthritis Biomarkers project, managed by the FNIH, will submit a comprehensive report, including imaging (i.e., MRI) and biochemical (i.e., urine, serum) biomarkers, for review by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA). Biomarker qualification is the result of a formal regulatory process that affirms a biomarker can be relied upon to have a specific interpretation and used in the review of a potential drug. The acceptance of these biomarkers for use in drug development will pave the way for improved clinical trials and treatments for knee OA.
